Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind,
repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6
compared to placebo over the course of 61 days in subjects with high BMI and evidence of
elevated liver fat.